Schizophrenia is a debilitating and chronic brain disorder which affects 1% of the world population. There is significant evidence to indicate high rates of smoking in this patient population causing additional health problems for this group of individuals. There is a scarcity of studies examining the effects of psychopharmacologic interventions in helping schizophrenic patients to either reduce or stop their tobacco intake. Recent evidence shows superiority of bupropion HCl to placebo in cigarette smoking cessation. Although cessation of smoking should be the ultimate goal, many schizophrenics are unwilling or unable to quit. We would like to test the hypothesis that bupropion will cause reductions in nicotine use by schizophrenic patients. We propose to do a double blind randomized placebo-controlled within subject cross-over study in 10 subjects to establish the feasibility and acceptability of bupropion in this population. We hope that this study will provide pilot data to undertake a subsequent larger, clinical trial.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2016) Longitudinal Care Improves Cessation in Smokers Who Do Not Initially Respond to Treatment by Increasing Cessation Self-Efficacy, Satisfaction, and Readiness to Quit: A Mediated Moderation Analysis. Ann Behav Med 50:58-69
Konorev, Dmitri; Koopmeiners, Joseph S; Tang, Yijin et al. (2015) Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking. Chem Res Toxicol 28:2390-9
Hatsukami, Dorothy K; Donny, Eric C; Koopmeiners, Joseph S et al. (2015) Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev 24:472-6
Burns, Rachel J; Rothman, Alexander J; Fu, Steven S et al. (2014) The relation between social support and smoking cessation: revisiting an established measure to improve prediction. Ann Behav Med 47:369-75
Oliver, Andrew J; Jensen, Joni A; Vogel, Rachel I et al. (2013) Flavored and nonflavored smokeless tobacco products: rate, pattern of use, and effects. Nicotine Tob Res 15:88-92
Knezevich, Aleksandar; Muzic, John; Hatsukami, Dorothy K et al. (2013) Nornicotine nitrosation in saliva and its relation to endogenous synthesis of N'-nitrosonornicotine in humans. Nicotine Tob Res 15:591-5
Anderson, Kristin E; Mongin, Steven J; Sinha, Rashmi et al. (2012) Pancreatic cancer risk: associations with meat-derived carcinogen intake in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort. Mol Carcinog 51:128-37
Stepanov, Irina; Knezevich, Aleksandar; Zhang, Liqin et al. (2012) Carcinogenic tobacco-specific N-nitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control 21:44-8
Henningfield, Jack E; Hatsukami, Dorothy K; Zeller, Mitch et al. (2011) Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. Drug Alcohol Depend 116:1-7
Hecht, Stephen S; Stepanov, Irina; Hatsukami, Dorothy K (2011) Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. Tob Control 20:443

Showing the most recent 10 out of 132 publications